Using attenuated salmonella typhi as tumor targeting vector for MDR1 siRNA delivery: An experimental study

Jiang, Zhong-ming; Zhao, Ping; Zhou, Zhonghua; Li, Jun; Qin, Lu-Ping; Wang, Hongwei

doi:10.4161/cbt.6.4.3850

Cited by 39 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, attenuated S. typhimurium were also successfully tested as a vector for in vivo transfer of MDR1 siRNA to tumors. 66 Combined oncolytic and siRNA therapy using systematically administered attenuated S. typhimurium expressing siRNA against tumor transcription factor STAT3 has also been evaluated. 67 Both of these studies demonstrated higher efficiency for combined therapy compared with treatment with nonRNAi-inducing bacteria.…”

Section: Transkingdom Rnaimentioning

confidence: 99%

Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy

et al. 2011

View full text Add to dashboard Cite

Several bacterial species have inherent ability to colonize solid tumors in vivo. However, their natural anti-tumor activity can be enhanced by genetic engineering that enables these bacteria express or transfer therapeutic molecules into target cells. In this review, we summarize latest research on cancer therapy using genetically modified bacteria with particular emphasis on blocking tumor angiogenesis. Despite recent progress, only a few recent studies on bacterial tumor therapy have focused on anti-angiogenesis. Bacteria-mediated anti-angiogenesis therapy for cancer, however, is an attractive approach given that solid tumors are often characterized by increased vascularization. Here, we discuss four different approaches for using modified bacteria as anti-cancer therapeutics-bactofection, DNA vaccination, alternative gene therapy and transkingdom RNA interference-with a specific focus on angiogenesis suppression. Critical areas and future directions for this field are also outlined.

show abstract

Section: Transkingdom Rnaimentioning

confidence: 99%

Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Delivery of small interfering RNA (siRNA) can be achieved through exogenous application of synthetic siRNA or through endogenous expression using plasmid or vector delivery to the target cells [21,22] . Chemically or enzymatically synthesized siRNA is costly and has been shown to have a relatively short half-life with only transient inhibition of the target gene because of its low transfection rate and short duration of interference.…”

Section: Discussionmentioning

confidence: 99%

Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer

Liu¹,

Bai²,

Yuan³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…Indeed, there are numerous compounds that can be delivered via bacteria to a tumor site including cytotoxic agents, green fluorescent protein for targeting and visualization of tumors, DNA for gene therapy, and small interfering RNAs (siRNA) to target expression of key proteins within tumors [11,22,26,27,28,29,30,31]. While these techniques have had varying levels of success in animal models, it is inferred that these practices when used in combination with the native toxicity of Salmonella may offer a fascinating alternative to traditional gene therapy approach.…”

Section: Using Salmonella To Deliver Anti Cancer Compoundsmentioning

confidence: 99%

Targeting Tumors with Salmonella Typhimurium - Potential for Therapy

2010

View full text Add to dashboard Cite

AbstrAct:When one considers the organism Salmonella enterica serotype Typhimurium (S. Typhimurium), one usually thinks of the Gram-negative enteric pathogen that causes the severe food borne illness, gastroentertitis. In this context, the idea of Salmonella being exploited as a cancer therapeutic seems pretty remote. However, there has been an escalating interest in the development of tumor-therapeutic bacteria for use in the treatment of a variety of cancers. This strategy takes advantage of the remarkable ability of certain bacteria to preferentially replicate and accumulate within tumors. In the case of S. Typhimurium, this organism infects and selectively grows within implanted tumors, achieving tumor/normal tissue ratios of approximately 1,000:1. Salmonella also has some attractive properties well suited for the design of a chemotherapeutic agent. In particular, this pathogen can easily be manipulated to carry foreign genes, and since this species is a facultative anaerobe, it is able to survival in both oxygenated and hypoxic conditions, implying this organism could colonize both small metastatic lesions as well as larger tumors. These observations are the impetus to a burgeoning field focused on the development of Salmonella as a clinically useful anti-cancer agent. We will discuss three cutting edge technologies employing Salmonella to target tumors.

show abstract

Using attenuated salmonella typhi as tumor targeting vector for MDR1 siRNA delivery: An experimental study

Cited by 39 publications

References 23 publications

Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy

Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy

Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer

Targeting Tumors with Salmonella Typhimurium - Potential for Therapy

Contact Info

Product

Resources

About